Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noradrenergic and cholinergic modulation of sleep and dreams
NL-OMON57413Recruiting
- Sponsor
- Netherlands Institute for Neuroscience
- Start
- Jan 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of atomoxetine, clonidine, donepezil and galantamine (4 arms), sponsored by Netherlands Institute for Neuroscience. Primary endpoints: EEG type I slow wave topography and amplitude and Mental experience reports and dream features. Started Jan 2026; status: recruiting.
02
Drugs
atomoxetineclonidinedonepezilgalantamine
Beyond the preview
Go deeper on NL-OMON57413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57413.